A newly developed broad-spectrum parasiticide treatment for dogs in an ever-changing landscape
Elanco’s acquisition of Bayer Animal Health positions Elanco as the world’s second largest provider of anti-parasitics. Elanco remains committed to ongoing investment in parasitology (including scientific studies presented at this WAAVP) and is now introducing Credelio Plus®, a novel oral endectocide for dogs. Active ingredients milbemycin oxime and lotilaner target larval and/or adult stages of various canine nematodes, and major tick and flea species, respectively.
Studies demonstrated Credelio Plus as highly effective (≥ 96.8%) against larval T. canis (L4) and A. caninum (immature adult L5). Efficacy against adult intestinal nematodes was confirmed by a multi-centre field study in veterinary practices in three European countries, proving to be highly efficacious (≥ 97.2%) in reducing the faecal egg count in dogs naturally infected with T. canis, A. caninum and T. vulpis.
The 100% prevention of heartworm disease is important considering many resistant isolates of D. immitis have been described from regions where this large multi-site field study was conducted. This study provided safety data in a long-term clinical setting with no dogs having treatment-related adverse reactions nor significant laboratory parameter alterations. In vitro genetic testing of 11 European isolates was conducted and compared to US isolates.
The three-month tick and flea field study demonstrated safety and efficacy against natural infestations by important species of ticks or fleas feeding on dogs, including the least susceptible arthropod R. sanguineus, and confirmed that dogs suffering from flea allergic dermatitis (FAD) may greatly benefit by administration of Credelio Plus.
- The new Elanco, following the acquisition of Bayer Animal Health
Patrick Meeus, Elanco, CH
- Internal parasite impacts of a newly approved endectocide
Brad Hayes, Elanco, UK
- Heartworm field study and genetic analysis of EU and US heartworm isolates
Lisa Young, Elanco, USA
- Ecto-parasite impacts of a newly approved endectocide
Sophie Forster, Elanco, UK
Key Topics: Parasites of companion animals; Anti-parasitic drugs and drug development; Arthropods; Helminths; Epidemiology